Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects

Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects

Ormutivimab is the first recombinant human anti-rabies monoclonal antibody (rhRIG) approved for clinical application in China. In this study, a population pharmacodynamic (PPD) model was established to compare the neutralizing antibody activities of Ormutivimab and human rabies immunoglobulin (HRIG)...

Full description

Bibliographic Details
Main Authors: Junnan Zhang, Nianmin Shi, Guohua Li, Li Li, Yunhua Bai, Liqing Yang, Weimin Zhao, Jian Gao, Jingshuang Wei, Wei Zhao, Lili Zhai, Peiyuan Huo, Lemin Ren, Lan Yu, Yufeng Li
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Vaccines
Subjects:
Ormutivimab
NONMEM
rabies
monoclonal antibody
rabies vaccine
Online Access:https://www.mdpi.com/2076-393X/10/8/1218

Internet

https://www.mdpi.com/2076-393X/10/8/1218

Similar Items